Mymetics Corporation, a Swiss developer of vaccines that use the human mucosal system to prevent transmission of infectious diseases, has promoted Ronald Kempers, formerly the company’s CFO and COO, to president and CEO. He has replaced Christopher Henney and Grant Pickering, who were director and chairman and president and CEO respectively and will pursue new strategic directions, including the potential change of Mymetics’ location from Switzerland to the US.
Mymetics will maintain its principal place of business in Switzerland as it explores a number of strategic opportunities for its HIV, RSV and other vaccine candidates under development.
The company will provide an update in due course.
